Mitigation of pre-existing immunogenicity in ADA method development

Key Points

• To address preexisting immunogenicity that interferes with the performance of ADA assays for ALXN-X.
• Developed a modified ADA assay to reduce interference from immunoglobulin-mediated reactivity.
• Tested the ability of the modified assay to detect ALXN-X-specific ADA.
• The modified assay significantly mitigated the interference from preexisting immunogenicity.
• Detection of ALXN-X-specific ADA was preserved, enhancing the reliability of immunogenicity assessments.